Leadership

The US Association for Accessible Medicines has named Lupin’s Bob Hoffman as its new chair. Meanwhile, departures have been seen at Stada and Dr Reddy’s, among other industry management changes.

Regulatory streamlining represents a paradigm shift for the biosimilars industry, but does it go far enough? Gillian Woollett, Samsung Bioepis’ head of regulatory strategy and policy, says streamlining must be accompanied by a sustainable economic environment for biosimilars to ensure global access.

Biocon Biologics has become one of the most prominent global biosimilars firms since its buyout of former partner Viatris’ biosimilars business. With a rumored IPO instead making way for a merger with generics unit Biocon Ltd, the business’s chief Shreehas Tambe sets out the reasons for the move.

A couple of months after leaving Hikma, former Custopharm CEO and Hikma injectables chief Bill Larkins has been named as the new president of Par Health’s injectables business.

As Denmark’s Orifarm announced the appointment of Jutta Schnirring-Mayer as chief business development and portfolio strategy officer – the latest in a line of management changes under new CEO Mads Fink Eriksen – the firm set out its ambitions to expand its European generics business.

Speaking exclusively to Generics Bulletin, Alvotech’s founder Robert Wessman explains why the company’s leadership split and Lisa Graver’s Iceland-based appointment as CEO mark a pivotal moment in its operational evolution.

Kicking off 2026 with a raft of changes, Medicines for Europe has appointed Zentiva CEO Steffen Saltofte as president while the IGBA has named CGPA head Jim Keon as chair for 2026. Meanwhile, Accord has named a new UK country head as ANI, Olpha, Outlook and Stada have announced management updates.

Alvotech has unveiled a planned leadership transition, with founder and chairman Róbert Wessman handing the chief executive role to long-time collaborator Lisa Graver as the biosimilars specialist prepares for its next phase of growth.

UK liquids specialist Rosemont Pharmaceuticals has named industry veteran Alok Sonig as its new CEO, as the firm continues to set its sights on the US market. Meanwhile, Rosemont has also appointed Gavin Wood as chief financial officer.

Hikma has initiated a leadership transition, with CEO Riad Mishlawi stepping down after just two years in the role, as margin pressure in its core Injectables business and operational delays weigh on performance.

After years of fighting and securing treatment for her daughter, cystic fibrosis campaigner Gayle Pledger could not leave other patients behind. This is a story of families coming together and finding a generic drug manufacturer in order to save their children.

In an exclusive interview, Generics Bulletin spoke to a trio of experts who argue that biosimilar cell and gene therapies are technically within reach but demand unprecedented regulatory clarity, manufacturing evolution and economic alignment before they become reality.

As Alvotech continues to reorganize its senior team with the promotion of chief scientific officer Joseph McClellan to chief operating officer, multiple other firms – including Hikma, Hyloris, CNX and Cingulate – have also announced executive updates.

Axplora made waves with a recent announcement that the API specialist’s total investments for 2025 would exceed €100m. Anant Barbadikar, co-president of the firm’s PharmaZell business unit, explains how the firm’s strategy is evolving and why he believes the future of pharma remains small-molecule.

In the wake of recent FDA guidance on streamlining the registration pathway for biosimilars, Organon’s head of US biosimilars, Jon Martin, talks to Generics Bulletin about how the company is re-evaluating the market landscape.

Hikma has started searching for a new Injectables head after Bill Larkins stepped down, at the same time as the firm has begun a reorganization of its R&D operations. Meanwhile, Stada has named a new head of Germany and Viatris has promoted a key executive in Europe.

In an exclusive interview with Generics Bulletin, Celltrion USA executives Tom Nusbickel and Juby Jacob-Nara discuss recent biosimilar launches, streamlining, moves into more innovative areas, and how Celltrion’s recent commitment to US manufacturing shows that the firm is “in it for the long run.”

With another regulator now considering the removal of clinical efficacy trials for biosimilars, BioPharmaSpec’s technical director Richard Easton paints the picture of data-powered biosimilarity assessment.

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.

Organon is looking for a new CEO after an internal investigation uncovered “improper wholesaler sales practices” relating to its Nexplanon implant. The firm will not revise any previously issued financial statements, despite saying that the tactics helped meet revenue expectations.